Compare UVE & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | XERS |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.6M | 1.0B |
| IPO Year | 1996 | 2021 |
| Metric | UVE | XERS |
|---|---|---|
| Price | $39.47 | $6.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $40.00 | $10.83 |
| AVG Volume (30 Days) | 192.1K | ★ 1.4M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 214.43 | 100.00 |
| EPS | ★ 1.88 | 0.01 |
| Revenue | ★ $1,603,915,000.00 | $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | $2.88 | $22.86 |
| P/E Ratio | $21.58 | ★ N/A |
| Revenue Growth | 5.48 | ★ 142.67 |
| 52 Week Low | $21.96 | $4.30 |
| 52 Week High | $41.96 | $10.08 |
| Indicator | UVE | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 59.81 | 57.52 |
| Support Level | $29.57 | $6.26 |
| Resistance Level | $41.96 | $7.21 |
| Average True Range (ATR) | 1.62 | 0.27 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 71.09 | 50.21 |
Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.